CINCINNATI , May 29, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny , Chief Executive Officer, and Bryan Baldasare , Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the 40 th Annual William Blair

CINCINNATI , May 26, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that its SARS-CoV-2 antigens and related reagents are part of assays granted U.S.

CINCINNATI , May 20, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience , Inc.’s (NASDAQ: VIVO) Board of Directors announced that Tony Serafini-Lamanna has been promoted to Executive Vice President of Diagnostics.  Jack Kenny remains Chief Executive Officer of Meridian, while passing responsibility of

CINCINNATI , May 08, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2020 . Second Quarter Fiscal 2020 Highlights: Consolidated Net Revenue of $57.3 million , up 14% year-over-year Life Science segment

CINCINNATI , May 06, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, is pleased to announce its collaboration with QuantuMDx on its newly launched SARS-CoV-2 assay for laboratory use.  The

CINCINNATI , April 30, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, has completed its previously announced acquisition of Exalenz Bioscience Ltd., the Modiin, Israel based provider of the BreathID ®

CINCINNATI , April 27, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today the launch of a novel enzyme master mix (Inhibitor Tolerant 1-step RT-qPCR Mix) that eliminates the need to use an RNA extraction kit prior to running the patient sample through a molecular

CINCINNATI , April 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report second quarter 2020 financial results Friday, May 8, 2020 . Jack Kenny , Chief Executive Officer, and Bryan Baldasare ,

CINCINNATI , April 14, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), announced today the launch of several novel recombinant antigens critical for the development of antibody tests for COVID-19. Since the emergence of COVID-19 outbreaks in January, Meridian has supported

CINCINNATI , April 02, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided a business update including preliminary revenue results for its second quarter of fiscal 2020.